POC Test Based on Quantum Dots Detects Antibody Responses
|
By LabMedica International staff writers Posted on 31 Oct 2019 |
|
Image: The Holomics Reader HRDR-300 mobile device was used to measure fluorescent intensity of the quantum dots complex after lateral migration of patient serum (Photo courtesy of Medical College of Georgia).
Point-of-care (POC) assays, which can be performed at or near the site of care with a rapid turnaround time, are pivotal to transforming global disease control efforts, particularly in resource-constrained settings where access to laboratory facilities is limited.
Cysticercosis is an infection caused by the larval form of the pork tapeworm Taenia solium. When larval cysts form in the human brain known as neurocysticercosis (NCC), they can result in seizures and other neurologic disorders. NCC affects those living in endemic and non-endemic countries, with an estimated more than 18,000 hospitalizations in the USA between 2003 and 2012.
Medical scientists at the Medical College of Georgia (Athens, GA, USA) and their international colleagues examined 112 positive human sera from patients with neurocysticercosis (NCC) including samples from 18 patients with single viable cyst, 71 patients with two or more viable cysts, and 23 patients with subarachnoid (racemose) cysts. Definitive diagnosis of the subject was established by computed-tomography and/or magnetic resonance imaging.
To test the specificity of the assay, the team evaluated a panel of serum samples obtained from 24 patients with other infections and 128 serum samples from persons in the USA and Egypt who had not traveled outside their country, and therefore were presumed negative for cysticercosis. The scientists developed a novel and portable fluorescent sensor that integrates a lateral flow assay with a quantum dot (Qdots) label and a mobile phone reader for detection of specific antibodies in human serum. They evaluated the utility of this assay to test for antibodies to the Taenia solium rT24H antigen.
The team read the lateral flow assay after 30 minutes, using the Holomics Reader HRDR-30. The investigators reported that the assay specificity in the negative panel was 99% (95%–100%) while assay sensitivity was 89% (79%–95%) in NCC patients with two or more viable cysts. The assay has performance characteristics similar to those of traditional platforms for the detection of NCC and shows promise as a mobile phone reader-based point-of-care test for antibody detection. The study was published on October 7, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Medical College of Georgia
Cysticercosis is an infection caused by the larval form of the pork tapeworm Taenia solium. When larval cysts form in the human brain known as neurocysticercosis (NCC), they can result in seizures and other neurologic disorders. NCC affects those living in endemic and non-endemic countries, with an estimated more than 18,000 hospitalizations in the USA between 2003 and 2012.
Medical scientists at the Medical College of Georgia (Athens, GA, USA) and their international colleagues examined 112 positive human sera from patients with neurocysticercosis (NCC) including samples from 18 patients with single viable cyst, 71 patients with two or more viable cysts, and 23 patients with subarachnoid (racemose) cysts. Definitive diagnosis of the subject was established by computed-tomography and/or magnetic resonance imaging.
To test the specificity of the assay, the team evaluated a panel of serum samples obtained from 24 patients with other infections and 128 serum samples from persons in the USA and Egypt who had not traveled outside their country, and therefore were presumed negative for cysticercosis. The scientists developed a novel and portable fluorescent sensor that integrates a lateral flow assay with a quantum dot (Qdots) label and a mobile phone reader for detection of specific antibodies in human serum. They evaluated the utility of this assay to test for antibodies to the Taenia solium rT24H antigen.
The team read the lateral flow assay after 30 minutes, using the Holomics Reader HRDR-30. The investigators reported that the assay specificity in the negative panel was 99% (95%–100%) while assay sensitivity was 89% (79%–95%) in NCC patients with two or more viable cysts. The assay has performance characteristics similar to those of traditional platforms for the detection of NCC and shows promise as a mobile phone reader-based point-of-care test for antibody detection. The study was published on October 7, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Medical College of Georgia
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Urine Analyzer
respons® UDS100
Latest Microbiology News
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read more
Molecular Diagnostics
view channel
New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
Bile duct strictures can arise from cancer or benign disease, but their location within ducts connecting the liver, gallbladder, and intestines complicates evaluation. Standard biopsy and cytology may... Read more
Adaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
PCR amplification during next-generation sequencing (NGS) library preparation can introduce variability, often requiring manual quantification and risking over-cycling artifacts. The issue is especially... Read more
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Microbiology
view channel
Rapid Urine Test Speeds Antibiotic Selection for UTIs
Urinary tract infections are a common reason for antibiotic prescribing and have led to more than 800,000 hospital admissions across England in the past five years, according to National Health Service data.... Read more
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read more
Pathology
view channel
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
Technology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Lunit (Seoul, South Korea), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta (Montreal, QC, Canada), a global contract research organization (CRO) laboratory serving... Read more
